Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
ID: 339464Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/339464

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)" aimed at supporting cancer epidemiology research through established cohort studies that have met their initial recruitment goals. This initiative encourages hypothesis-driven research utilizing existing cohort data, with a focus on maintaining cohorts, continuing participant follow-up, and optimizing resource sharing across the cancer control continuum. Eligible applicants include a diverse range of institutions, such as higher education institutions, nonprofits, and foreign organizations, with projects expected to last up to five years and no specific budget limits, although costs must align with project needs. Interested parties should note that the application deadline is February 28, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. For further details, applicants can refer to the full announcement available at http://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-162-Full-Announcement.html
    PAR-22-162.html
    The National Cancer Institute (NCI) has announced a Funding Opportunity Announcement (FOA) aimed at supporting research in established cancer epidemiology cohort studies, specifically targeting projects that have met their original recruitment goals. The FOA (PAR-22-162) encourages applications focusing on hypothesis-driven research and aims to facilitate cohort maintenance, continue participant follow-up, and optimize the use of existing resources across the cancer control continuum. Eligible applicants include higher education institutions, nonprofits, state/local governments, and foreign institutions. The maximum project duration is five years, with no specific budget limits, but costs must reflect actual project needs. Submitted applications will undergo a thorough review based on significance, investigator qualifications, innovation, approach, and the research environment, and proposals linked to understudied populations or cancer risk factors will be especially favored. This initiative highlights NCI's investment in leveraging existing data to enhance understanding of cancer determinants and support interventions while providing a collaborative framework for awardees through a cohort program steering committee. Each awarded project will involve considerable NIH involvement, emphasizing effective data sharing and research responsiveness.
    Similar Opportunities
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.